Alexion Pharmaceuticals Inc.
352 Knotter Drive
About Alexion Pharmaceuticals Inc.Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.
Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).
Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
549 articles with Alexion Pharmaceuticals Inc.
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018.
Brings in clinical-stage anti-FcRn antibody SYNT001 with potential to address a number of rare IgG-mediated diseases
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune have just today announced that Alexion will be acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn).
Alexion Pharmaceuticals today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 10 a.m., EDT.
Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neur...
9/24/2018Soliris® Reduced the Risk of Adjudicated On-Trial Relapse by 94.2% Compared to Placebo (p < 0.0001).
In the biotech hub area known as Pharm Country, the small state of Rhode Island often gets overlooked in favor of its larger neighbors, such as New York, New Jersey and Pennsylvania. But, the Ocean State is making some moves to enhance its image as a biotech hub, particularly in the wake of some ...
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
Alexion Pharmaceuticals today announced that management will present at Morgan Stanley’s 16th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT.
Alexion Pharmaceuticals today announced that management will present at Citi’s 13th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.m., EDT.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs.
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US
EU Filing Accepted and Under Review
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—...
Alexion Pharmaceuticals, Inc. today announced financial results for the second quarter of 2018.
Cardurion Pharmaceuticals, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.
Free Technical Research Reports on Biotech Stocks -- Alkermes, Alnylam Pharma, Altimmune, and Alexion Pharma
On Monday, July 23, 2018, the NASDAQ Composite closed the trading session at 7,841.87, up 0.28%; the Dow Jones Industrial Average edged 0.06% lower, to finish at 25,044.29; and the S&P 500 closed at 2,806.98, slightly advancing 0.18%.
7/9/2018Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)
Alexion Pharmaceuticals, Inc. today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210.